Findings

What do systematic reviews say?

461 questions · 472 findings · 42 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 93 · 19.7%GRADE not reported 81 · 17.2%Very low 99 · 21%Low 103 · 21.8%Moderate 75 · 15.9%High 21 · 4.4%

Low‐level laser therapy vs placebo

Adverse events · carpal tunnel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Low‐level laser therapy for carpal tunnel syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo or no treatment

Incomplete recovery at end of study House‐Brackmann scale, Sunnybrook score, Yanagihara score · Bell's palsy

Corticosteroids leads to lower incomplete recovery ≥ 6 months after randomisation House‐Brackmann… compared with placebo or no treatment (high certainty).

1 finding from 1 review

Corticosteroids for Bell's palsy (idiopathic facial paralysis) 2016 · Cochrane Headline outcomes only
RR 0.63 [0.5, 0.8]
7 studies · 895 participants
High

Corticosteroids vs placebo or no treatment

Cosmetically disabling persistent sequelae ≥ 6 months after randomisation Clinical assessment · Bell's palsy

Corticosteroids showed no clear difference in cosmetically disabling persistent sequelae ≥ 6 months after… compared with placebo or no treatment (low certainty).

1 finding from 1 review

Corticosteroids for Bell's palsy (idiopathic facial paralysis) 2016 · Cochrane Headline outcomes only
RR 0.96 [0.4, 2.29]
2 studies · 75 participants
Low

Corticosteroids vs placebo or no treatment

Motor synkinesis or crocodile tears Clinical assessment · Bell's palsy

Corticosteroids probably leads to lower motor synkinesis and crocodile tears Clinical assessment compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Corticosteroids for Bell's palsy (idiopathic facial paralysis) 2016 · Cochrane Headline outcomes only
RR 0.64 [0.45, 0.91]
3 studies · 485 participants
Moderate

Corticosteroids vs placebo or no treatment

Adverse effects · Bell's palsy

Corticosteroids showed no clear difference in adverse effects compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Corticosteroids for Bell's palsy (idiopathic facial paralysis) 2016 · Cochrane Headline outcomes only
RR 1.04 [0.71, 1.51]
3 studies · 715 participants
Moderate

Rituximab vs placebo

Number of participants improved in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

Rituximab may leads to higher number of participants improved in disability compared with placebo (low certainty).

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
RR 3.51 [1.3, 9.45]
2 studies · 73 participants
Low

Rituximab vs placebo

Mean improvement in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 73 participants
Low

Rituximab vs placebo

Improvement in 10‐metre walk time at 8 to 12 months1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 68 participants
Moderate

Rituximab vs placebo

Participant subjective impression of change stable or improved at 8 to 12 months · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

Rituximab may leads to higher participant subjective impression of change stable or improved at 8… compared with placebo (low certainty).

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
RR 1.86 [1.27, 2.71]
2 studies · 70 participants
Low

Rituximab vs placebo

Change in serum IgM paraprotein concentration 8 months after treatment1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Moderate

Rituximab vs placebo

Any adverse event · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

It is very uncertain whether rituximab changes any adverse event compared with placebo (very low certainty).

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
RR 1.18 [0.84, 1.66]
2 studies · 80 participants
Very low

Corticosteroids vs placebo

Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

Mean change in average muscle score: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 147 participants
Moderate

Corticosteroids vs placebo

Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 111 participants
Moderate

Corticosteroids vs placebo

4‐stair climbing time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 152 participants
Moderate

Corticosteroids vs placebo

Weight gain · patients with Duchenne muscular dystrophy

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 126 participants
Moderate

Corticosteroids vs placebo

Behavioural changes ‐ prednisone (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy

Corticosteroids showed no clear difference in behavioural changes ‐ prednisone (0.75 mg/kg/day) compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
RR 1.39 [0.94, 2.06]
2 studies · 135 participants
Moderate

Corticosteroids vs placebo

Fracture · patients with Duchenne muscular dystrophy

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 143 participants
GRADE not reported

Corticosteroids vs placebo

Improvement in sensory nerve function at 1 year · people with nerve damage (< 6 months' duration) in leprosy

Corticosteroids showed no clear difference in improvement in sensory nerve function at 1 year Defined as a… compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroids for treating nerve damage in leprosy 2016 · Cochrane Headline outcomes only
RR 1.01 [0.81, 1.27]
1 study · 75 participants
Moderate

Corticosteroids vs placebo

Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for treating nerve damage in leprosy 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found